Hosford D, Paubert-Braquet M, Braquet P
Institute Henri Beaufour, Le Plessis Robinson, France.
Resuscitation. 1989 Dec;18(2-3):207-18. doi: 10.1016/0300-9572(89)90023-3.
Many types of shock are characterized by profound hemodynamic alterations and depression of immune processes. Among the various mediators implicated in shock conditions, there is much evidence to suggest that, together with various cytokines, the inflammatory and chemotactic autacoid, platelet-activating factor (PAF), plays an important role. Studies on several animal models have shown that infusion of PAF mimicks the shock state, that markedly increased levels of PAF are produced in shock and that PAF antagonists afford significant protection against diverse forms of shock. The precise mechanism by which PAF antagonists protect against shock remains unclear; however, it is becoming apparent that in traumatic states a complex interaction occurs between PAF and cytokines, which leads to the acute phase reaction and circulatory collapse. We propose that PAF antagonists may be effective in counteracting shock because of their antiprotease activity and their ability to inhibit deleterious PAF/cytokine auto-generated feedback processes.
许多类型的休克都具有深刻的血流动力学改变和免疫过程抑制的特征。在与休克状态相关的各种介质中,有大量证据表明,炎症趋化自分泌素血小板活化因子(PAF)与各种细胞因子一起发挥着重要作用。对几种动物模型的研究表明,输注PAF可模拟休克状态,休克时PAF水平显著升高,且PAF拮抗剂能为多种形式的休克提供显著保护。PAF拮抗剂预防休克的确切机制尚不清楚;然而,越来越明显的是,在创伤状态下,PAF与细胞因子之间会发生复杂的相互作用,从而导致急性期反应和循环衰竭。我们认为,PAF拮抗剂可能因其抗蛋白酶活性以及抑制有害的PAF/细胞因子自分泌反馈过程的能力而有效地对抗休克。